Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
17.80
-0.15 (-0.84%)
At close: Mar 6, 2026, 4:00 PM EST
17.99
+0.19 (1.07%)
After-hours: Mar 6, 2026, 6:46 PM EST

Monte Rosa Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
181.5475.62----
Revenue Growth (YoY)
1112.27%-----
Gross Profit
181.5475.62----
Selling, General & Admin
34.6435.1732.0427.3215.734.01
Research & Development
138.39121.56111.2785.0657.1624.01
Total Operating Expenses
173.03156.73143.31112.3872.8828.01
Operating Income
8.51-81.11-143.31-112.38-72.88-28.01
Interest Income
11.8510.579.333.760.050.01
Other Non-Operating Income (Expense)
1.60.42-0.780.12-1.12-7.88
Total Non-Operating Income (Expense)
13.4410.988.33.88-1.08-7.87
Pretax Income
21.95-70.13-135.01-108.5-73.96-35.88
Provision for Income Taxes
1.012.570.34---
Net Income
20.95-72.7-135.35-108.5-73.96-35.88
Net Income to Common
20.95-72.7-135.35-108.5-73.96-35.88
Shares Outstanding (Basic)
82745147252
Shares Outstanding (Diluted)
82745147252
Shares Change (YoY)
21.95%43.80%8.83%88.91%1548.09%7.11%
EPS (Basic)
0.32-0.98-2.63-2.30-2.96-23.65
EPS (Diluted)
0.32-0.98-2.63-2.30-2.96-23.65
Free Cash Flow
145.0238.01-62.84-105.38-69.1-26.44
Free Cash Flow Growth
281.56%-----
Free Cash Flow Per Share
1.760.51-1.22-2.23-2.76-17.43
Gross Margin
100.00%100.00%----
Operating Margin
4.69%-107.26%----
Profit Margin
11.54%-96.14%----
FCF Margin
79.89%50.26%----
EBITDA
16.84-72.99-137.09-108.64-70.75-27.47
EBITDA Margin
9.28%-96.52%----
EBIT
8.51-81.11-143.31-112.38-72.88-28.01
EBIT Margin
4.69%-107.26%----
Effective Tax Rate
4.59%-3.66%-0.25%0.00%0.00%0.00%
Updated Nov 6, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q